Exclusive: Bucking gene editing downturn, Tune raises $175M to bring epigenetic editing to clinic - Endpoints News
Tune Therapeutics raises $175M Series B for epigenetic editing, with hepatitis B drug Tune-401 in the clinic. NEA, Yosemite, Regeneron Ventures led funding.
Comments